BR0012865A - Uma forma amorfa aperfeiçoada da proxetil cefpodoxima - Google Patents

Uma forma amorfa aperfeiçoada da proxetil cefpodoxima

Info

Publication number
BR0012865A
BR0012865A BR0012865-1A BR0012865A BR0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A
Authority
BR
Brazil
Prior art keywords
amorphous form
improved
cefpodoxime proxetil
improved amorphous
proxetyl
Prior art date
Application number
BR0012865-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Yatendra Kumar
Rakesh Kumar Arora
Kaptan Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0012865A publication Critical patent/BR0012865A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0012865-1A 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima BR0012865A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1999-07-30 1999-07-30
PCT/IB2000/001024 WO2001009143A1 (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil

Publications (1)

Publication Number Publication Date
BR0012865A true BR0012865A (pt) 2002-07-09

Family

ID=11092065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012865-1A BR0012865A (pt) 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima

Country Status (9)

Country Link
US (1) US6602999B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1204667A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2003506329A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1371381A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU5839100A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0012865A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN191496B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001009143A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200200692B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408226B (de) * 1999-05-05 2001-09-25 Biochemie Gmbh Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
US7045618B2 (en) 2001-02-27 2006-05-16 Ranbaxy Laboratories Limited Cefpodixime proxetil
TW200942516A (en) * 2004-10-18 2009-10-16 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
KR20080026109A (ko) * 2005-05-16 2008-03-24 엘란 파마 인터내셔널 리미티드 세팔로스포린을 함유하는 나노입자형 조절 방출 조성물
KR100840132B1 (ko) * 2007-04-17 2008-06-23 재단법인서울대학교산학협력재단 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
EP3725778B1 (en) 2012-09-11 2021-08-18 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
KR20150053963A (ko) * 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN108884111A (zh) * 2016-05-09 2018-11-23 苏州科睿思制药有限公司 克立硼罗游离形式的晶型及其制备方法和用途
EP3472172A1 (en) * 2016-06-16 2019-04-24 Xenon Pharmaceuticals Inc. Solid state forms of spiro-oxindole compounds
WO2018046337A1 (en) * 2016-09-06 2018-03-15 Indena S.P.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
CA3034648C (en) 2016-09-07 2023-02-28 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
IL295609B2 (en) * 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
MX2020005348A (es) * 2017-11-22 2020-08-13 Agios Pharmaceuticals Inc Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
WO2019195753A1 (en) * 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) * 2019-08-14 2021-12-07 中国药科大学 头孢泊肟酯柚皮素共无定形物及其制备方法
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
WO2023228905A1 (ja) 2022-05-23 2023-11-30 国立大学法人名古屋工業大学 湿式紡糸法を用いて無機フィラー粒子を含有する生分解性繊維材料を連続的に製造する方法、及びその方法で製造された綿形状の骨再生材料

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
DE59209994D1 (de) * 1991-09-07 2004-04-29 Aventis Pharma Gmbh Diastereomer des 3-Cephem-4-carbonsäure-1-(-isopropoxycarbonyloxy)ethylesters und Verfahren zu dessen Herstellung
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
WO2001009143A1 (en) 2001-02-08
JP2003506329A (ja) 2003-02-18
US6602999B1 (en) 2003-08-05
CN1371381A (zh) 2002-09-25
ZA200200692B (en) 2003-05-28
IN191496B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2003-12-06
EP1204667A4 (en) 2002-10-30
EP1204667A1 (en) 2002-05-15
AU5839100A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
BR0012865A (pt) Uma forma amorfa aperfeiçoada da proxetil cefpodoxima
Deshpande et al. Degradation of β-lactam antibiotics
CA1037949A (en) Cephalosporin derivatives
UY23757A1 (es) Procedimiento para la preparación de derivados de cefalosporina.-
BR0112598A (pt) Processo para a preparação de (r,s)-axetil cefuroxima cristalina de alta pureza
CA2103696A1 (en) A method for the acylation of the 7-amino group of the cephalosporanic ring
KR100667143B1 (ko) 가용성 측쇄 에스테르와 효소 아실라제를 사용하는 β-락탐 항균 물질의 합성법
US6919449B2 (en) Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds
CA2292618C (en) Improved precipitation process of 7-aminocephalosporanic acid (7-aca)
WO2003011871A3 (en) Intermediates in cephalosporin production
KR910018388A (ko) 세팔로스포린 제조방방방법
CN100368554C (zh) 酶催化“一锅法”制备β-内酰胺抗生素的方法
BR9301627A (pt) Processo para preparar cefalosporinas
EP1600499A4 (en) PROCESS FOR THE PRODUCTION OF LACTONASE AND USE THEREOF
ATE244248T1 (de) Herstellung von amino cephalosporansäurederivaten
MXPA03001333A (es) Butinol i esterasa.
GB1496351A (en) 2-substituted ceph-3-em-4-carboxylic acid derivatives
DE60233307D1 (de) Verfahren zur herstellung optisch aktiver propoxyanilinderivate
FI58132B (fi) Foerfarande foer framstaellning av 3-metyl- 3-cefem-4-karboxylsyrafoereningar
EP0742219B1 (en) Preparation and use of 7-((2-carbo-alkoxy-1-methylethenyl) amino)-3-hydroxymethyl-3-cephem-4-carboxylic acids
WO2004081220A3 (en) A process for enzymatically resolving an enantiomeric mixture of alpha-hydroxy acids
AU2002224397A1 (en) Synthesis of acid addition salt of delta-aminolevulinic acid from 5-bromo levulinic acid esters
KR890000497A (ko) 아실 유도체
IE46175L (en) Preparation of 3-heterocyclylthiomethyl cephalosporins from¹3-methylene cephalosporins.
DE60044276D1 (de) Esterase Gene und Verwendungen davon

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired